Loading...
XSTO
QLIFE
Market cap2mUSD
Dec 05, Last price  
1.56SEK
1D
23.81%
1Q
-55.93%
IPO
-83.57%
Name

Qlife Holding AB

Chart & Performance

D1W1MN
XSTO:QLIFE chart
P/E
P/S
218.84
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
-62.25%
Revenues
89k
-63.52%
11,616,00020,750,00039,613,00017,993,000244,00089,000
Net income
-56m
L-65.00%
-5,271,413-20,200,000-38,797,000-93,141,000-159,956,000-55,981,000
CFO
-37m
L-10.59%
-3,879,940-16,829,000-26,051,000-47,733,000-41,798,000-37,370,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents. The company offers Egoo.Health Platform, an integrated platform with a measuring instrument with disposable capsules and software, where each capsule contains a test for a specific biomarker or virus. Its biomarkers include C-reactive protein home-testing capsule, PHE/Phenylalanine for PKU patients, and Sars-CoV-2/Influenza multiplex for virus/bacteria tests. The company was incorporated in 2019 and is based in Helsingborg, Sweden.
IPO date
Mar 02, 2020
Employees
26
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT